Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Jun 21, 2021 2:38pm
137 Views
Post# 33421335

RE:RE:RE:RE:RE:RE:RE:Q&A indicates LSA has brought some good new investors

RE:RE:RE:RE:RE:RE:RE:Q&A indicates LSA has brought some good new investors

If we see it work, that will likely be the way to stay independent and maximize the value.  If a big pharma buys, they are less likely to license it out to serious competitors in similar spaces.  THTX may not have that issue and can license it to both big pharma competitors using, say, their latest TKIs or Immunolncology drugs.   It's almost more valuable as an independent with multiple partnerships or licenses for individual drugs.  

JFM on the work they are doing with the "best imaging company", for the tests you have highlighted, do you think it's the people you mentioned "down the road" in Laval? I think you said that's where a diagnostic company doing ground breaking imaging work was located.  


jfm1330 wrote: Beliveau subtly looked and sounded like the cat that ate the canary... He is the guy at the basis of all that. The key here is the nature of the sortilin receptor as a scavenger receptor that expresses itself more and more as a cancer evolves into a more agressive stage. Other than that, We now know why they take all comers, it confirms what I thought, but we now know that they take biopsies along the way, so it will not cause problems to determine the maximun tolerable dose in patients with tumors overexpressing sortilin. The data on metastatic inhibition is impressive, even though it is just on mice. 

I was the first to be very positive on oncology here after the bought Katana and to say it had the potential to become the main asset of the company and to get to the market much faster than tesamorelin in NASH. After what I saw and heard today, I am even more positive. Again, this is not one drug, it is the possibility of multiple new molecular entities, and also, they are just scratching the surface if it really works. The possibilities for combination therapy with other cancer drugs is huge, also, you can think of combination therapy with two cytotoxic agents linked to TH19P01. Imagine TH1902 (TH19P01-docetaxel) given at the same time as TH19P01-Lu177. You could selectively attack the cancer in two ways, even three ways. If it works, they will need good imagination to figure all the ways this peptide could be used. And again, companies with proprietary cancer drugs will come knocking on their door. Imagine, they will be able to out licence the peptide for use with a specific proprietary cancer drugs, just collecting royalties!

 

SPCEO1 wrote: Like Wino, I asked a commercially oriented question that was ignored. I suspect LSA wanted to keep this one focused on science.

qwerty22 wrote:

That was one thing missing any talk about commercial, comparable companies, ADC market etc

 

Wino115 wrote: I think we snuffed out your's and JFMs questions -- the 2nd MOA one and the imaging one.
Mine didn't get asked as it was to crass I guess -- what do you think is the commercial opportunity for this platform?  and , do you think clinics will use it at the 2L and 3L level if sortilin is expressed enough?
 

 

qwerty22 wrote:

I got two Qs asked

 

Wino115 wrote:

 

Or JFM Scarlet  and QWERTY stuffed the Q&A box.  

 

SPCEO1 wrote: Very scientific questions indicate to me that US based institutions are indeed on this call - a very good sign for LSA's capabilities.

 

 


 

 

 

 




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse